Beam Therapeutics(US:BEAM) ZACKS·2026-02-24 14:51分组1 - Beam Therapeutics Inc. reported a quarterly loss of $0.1 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.13, representing an earnings surprise of +91.15% [1] - The company posted revenues of $114.11 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 676.25%, compared to revenues of $30.07 million a year ago [2] - Beam Therapeutics shares have increased by approximately 2.2% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] 分组2 - The earnings outlook for Beam Therapeutics is uncertain, with current consensus EPS estimates at -$1.14 on revenues of $15.49 million for the coming quarter and -$4.63 on revenues of $55.85 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The estimate revisions trend for Beam Therapeutics was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]